Antidote Technologies and SEQSTER Join Forces to Improve Patient Identification & Enrollment for Clinical Trials
Shots:
- Antidote and SEQSTER have collaborated to improve patient identification & recruitment as well as enhance trial timelines for healthcare firms
- Antidote will combine its screening and support services and SEQSTER Operating System to identify patients for clinical studies after looking into their comprehensive medical history, genomic data & lifestyle factors, expediting enrollment for trials
- The partnership between SEQSTER and Antidote streamlines patient enrollment, reducing trial startup time. Antidote's personalized services and SEQSTER's technology will further improve patient engagement & adherence to trial protocols and data accuracy
Ref: Antidote | Image: Antidote
Related News:- Boehringer Ingelheim Collaborates with Walgreens to Improve Clinical Trials Access
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
